Pseudomonas aeruginosa, a Gram-negative bacterium, is a member of the ESKAPE pathogens and one of the leading causes of healthcare-associated infections worldwide. Aminoglycosides (AGs) are recognized for their efficacy against P. aeruginosa. The most common resistance mechanism against AGs is the acquisition of AG-modifying enzymes (AMEs) by the bacteria, including AG N-acetyltransferases (AACs), AG O-phosphotransferases (APHs), and AG O-nucleotidyltransferases (ANTs). In this study, we obtained 122 multidrug-resistant P. aeruginosa clinical isolates and evaluated the antibacterial effects of six AGs and two carbapenems alone against all clinical isolates, and in combination against eight selected strains. We further probed for four representatives of the most common AME genes [aac(6′)-Ib, aac(3)-IV, ant(2")-Ia, and aph(3′)-Ia] by polymerase chain reaction (PCR) and compared the AME patterns of these 122 clinical isolates to their antibiotic resistance profile. Among the diverse antibiotics resistance profile displayed by these clinical isolates, we found correlations between the resistance to various AGs as well as between the resistance to one AG and the resistance to carbapenems. PCR results revealed that the presence of aac(6′)-Ib renders these isolates more resistant to a variety of antibiotics. The correlation between resistance to various AGs and carbapenems partially reflects the complex resistance strategies adapted in these pathogens and encourages the development of strategic treatment for each P. aeruginosa infection by considering the genetic information of each isolated bacteria.
Get full access to this article
View all access options for this article.
References
1.
BoucherH.W., TalbotG.H., BradleyJ.S., EdwardsJ.E., GilbertD., RiceL.B., ScheldM., SpellbergB., and BartlettJ.. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis., 48:1–12.
2.
NartenM., RosinN., SchobertM., and TielenP.. 2012. Susceptibility of Pseudomonas aeruginosa urinary tract isolates and influence of urinary tract conditions on antibiotic tolerance. Curr. Microbiol., 64:7–16.
3.
ObritschM.D., FishD.N., MacLarenR., and JungR.. 2005. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy., 25:1353–1364.
4.
PendletonJ.N., GormanS.P., and GilmoreB.F.. 2013. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti Infect. Ther., 11:297–308.
5.
PobiegaM., MaciagJ., ChmielarczykA., RomaniszynD., Pomorska-WesolowskaM., ZiolkowskiG., HeczkoP.B., BulandaM., and Wojkowska-MachJ.. 2015. Molecular characterization of carbapenem-resistant Pseudomonas aeruginosa strains isolated from patients with urinary tract infections in Southern Poland. Diagn. Microbiol. Infect. Dis., 83:295–297.
6.
QiuX., KulasekaraB.R., and LoryS.. 2009. Role of horizontal gene transfer in the evolution of Pseudomonas aeruginosa virulence. Genome Dyn., 6:126–139.
7.
RiceL.B.2010. Progress and challenges in implementing the research on ESKAPE pathogens. Infect. Control Hosp. Epidemiol., 31Suppl 1:S7–S10.
8.
HirschE.B., and TamV.H.. 2010. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev. Pharmacoecon. Outcomes Res., 10:441–451.
9.
National Nosocomial Infection Surveillance (NNIS) system report: data summary from January 1992 through June 2003. Available at www.cdc.gov/ncidod/dhqp/pdf (accessed July13, 2017).
10.
FujitaniS., MoffettK.S., and YuV.L.. 2017. Pseudomonas aeruginosa, antimicrobe: infectious disease & antimicrobial agents. Available at www.antimicrobe.org/new/b112.asp (accessed July13, 2017).
11.
CalhounJ.H., MurrayC.K., and ManringM.M.. 2008. Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin. Orthop. Relat. Res., 466:1356–1362.
12.
FossoM.Y., LiY., and Garneau-TsodikovaS.. 2014. New trends in aminoglycosides use. MedChemComm, 5:1075–1091.
13.
MattT., NgC.L., LangK., ShaS.H., AkbergenovR., ShcherbakovD., MeyerM., DuschaS., XieJ., DubbakaS.R., Perez-FernandezD., VasellaA., RamakrishnanV., SchachtJ., and BottgerE.C.. 2012. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc. Natl. Acad. Sci. U. S. A., 109:10984–10989.
14.
KangA.D., SmithK.P., EliopoulosG.M., BergA.H., McCoyC., and KirbyJ.E.. 2017. In vitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis., 88:188–191.
15.
KarlowskyJ.A., HobanD.J., HackelM.A., LobS.H., and SahmD.F.. 2017. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013–2015. J. Med. Microbiol., 66:61–69.
16.
BiedenbachD.J., GiaoP.T., Hung VanP., Su Minh TuyetN., Thi Thanh NgaT., PhuongD.M., Vu TrungN., and BadalR.E.. 2016. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii from patients with hospital-acquired or ventilator-associated pneumonia in Vietnam. Clin. Ther., 38:2098–2105.
17.
ChenW., BiswasT., PorterV.R., TsodikovO.V., and Garneau-TsodikovaS.. 2011. Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB. Proc. Natl. Acad. Sci. U. S. A., 108:9804–9808.
18.
ChenW., GreenK.D., TsodikovO.V., and Garneau-TsodikovaS.. 2012. Aminoglycoside multiacetylating activity of the enhanced intracellular survival protein from Mycobacterium smegmatis and its inhibition. Biochemistry, 51:4959–4967.
19.
GreenK.D., ChenW., and Garneau-TsodikovaS.. 2012. Identification and characterization of inhibitors of the aminoglycoside resistance acetyltransferase Eis from Mycobacterium tuberculosis. ChemMedChem, 7:73–77.
20.
HoughtonJ.L., GreenK.D., PricerR.E., MayhoubA.S., and Garneau-TsodikovaS.. 2013. Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes. J. Antimicrob. Chemother., 68:800–805.
21.
HoughtonJ.L., BiswasT., ChenW., TsodikovO.V., and Garneau-TsodikovaS.. 2013. Chemical and structural insights into the regioversatility of the aminoglycoside acetyltransferase Eis. ChemBioChem, 14:2127–2135.
22.
TsodikovO.V., GreenK.D., and Garneau-TsodikovaS.. 2014. A random sequential mechanism of aminoglycoside acetylation by Mycobacterium tuberculosis Eis protein. PLoS One, 9:e92370.
23.
RamirezM.S., and TolmaskyM.E.. 2010. Aminoglycoside modifying enzymes. Drug Resist. Updat., 13:151–171.
24.
HoughtonJ.L., GreenK.D., ChenW., and Garneau-TsodikovaS.. 2010. The future of aminoglycosides: the end or renaissance?. ChemBioChem, 11:880–902.
25.
LiY., GreenK.D., JohnsonB.R., and Garneau-TsodikovaS.. 2015. Inhibition of aminoglycoside acetyltransferase resistance enzymes by metal salts. Antimicrob. Agents Chemother., 59:4148–4156.
26.
ShaulP., GreenK.D., RutenbergR., KramerM., Berkov-ZrihenY., Breiner-GoldsteinE., Garneau-TsodikovaS., and FridmanM.. 2011. Assessment of 6′- and 6′′′-N-acylation of aminoglycosides as a strategy to overcome bacterial resistance. Org. Biomol. Chem., 9:4057–4063.
27.
GreenK.D., ChenW., and Garneau-TsodikovaS.. 2011. Effects of altering aminoglycoside structures on bacterial resistance enzyme activities. Antimicrob. Agents Chemother., 55:3207–3213.
28.
Chandrika ThambanN., GreenK.D., HoughtonJ.L., and Garneau-TsodikovaS.. 2015. Synthesis and biological activity of mono- and di-N-acylated aminoglycosides. ACS Med. Chem. Lett., 6:1134–1139.
29.
FongD.H., XiongB., HwangJ., and BerghuisA.M.. 2011. Crystal structures of two aminoglycoside kinases bound with a eukaryotic protein kinase inhibitor. PLoS One, 6:e19589.
30.
LopezC., ArivettB.A., ActisL.A., and TolmaskyM.E.. 2015. Inhibition of AAC(6′)-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2′,4′-bridged nucleic acid-NC-DNA hybrid oligomer. Antimicrob. Agents Chemother., 59:5798–5803.
31.
ShakyaT., StogiosP.J., WaglechnerN., EvdokimovaE., EjimL., BlanchardJ.E., McArthurA.G., SavchenkoA., and WrightG.D.. 2011. A small molecule discrimination map of the antibiotic resistance kinome. Chem. Biol., 18:1591–1601.
32.
WelchK.T., VirgaK.G., WhittemoreN.A., OzenC., WrightE., BrownC.L., LeeR.E., and SerpersuE.H.. 2005. Discovery of non-carbohydrate inhibitors of aminoglycoside-modifying enzymes. Bioorg. Med. Chem., 13:6252–6263.
33.
ZhangW., ChenY., LiangQ., LiH., JinH., ZhangL., MengX., and LiZ.. 2013. Design, synthesis, and antibacterial activities of conformationally constrained kanamycin A derivatives. J. Org. Chem., 78:400–409.
34.
FairR.J., HenslerM.E., ThienphrapaW., DamQ.N., NizetV., and TorY.. 2012. Selectively guanidinylated aminoglycosides as antibiotics. ChemMedChem, 7:1237–1244.
35.
TsaiA., UemuraS., JohanssonM., PuglisiE.V., MarshallR.A., AitkenC.E., KorlachJ., EhrenbergM., and PuglisiJ.D.. 2013. The impact of aminoglycosides on the dynamics of translation elongation. Cell Rep., 3:497–508.
36.
Llano-SoteloB., HickersonR.P., LancasterL., NollerH.F., and MankinA.S.. 2009. Fluorescently labeled ribosomes as a tool for analyzing antibiotic binding. RNA, 15:1597–1604.
37.
ChangC.W., FossoM., KawasakiY., ShresthaS., BensaciM.F., WangJ., EvansC.K., and TakemotoJ.Y.. 2010. Antibacterial to antifungal conversion of neamine aminoglycosides through alkyl modification. Strategy for reviving old drugs into agrofungicides. J. Antibiot., 63:667–672.
DuschaS., BoukariH., ShcherbakovD., SalianS., SilvaS., KendallA., KatoT., AkbergenovR., Perez-FernandezD., BernetB., VaddiS., ThommesP., SchachtJ., CrichD., VasellaA., and BottgerE.C.. 2014. Identification and evaluation of improved 4′-O-(alkyl) 4,5-disubstituted 2-deoxystreptamines as next-generation aminoglycoside antibiotics. mBio., 5:e01827-01814.
40.
NakamuraA., HosodaM., KatoT., YamadaY., ItohM., KanazawaK., and NoudaH.. 2000. Combined effects of meropenem and aminoglycosides on Pseudomonas aeruginosa in vitro. J. Antimicrob. Chemother., 46:901–904.
41.
FerraraA., GrassiG., GrassiF.A., PiccioniP.D., and Gialdroni GrassiG.. 1989. Bactericidal activity of meropenem and interactions with other antibiotics. J. Antimicrob. Chemother., 24Suppl A:239–250.
42.
KropecA., LemmenS., WursthornM., and DaschnerF.D.. 1994. Combination effect of meropenem with aminoglycosides and teicoplanin on Pseudomonas and enterococci. Infection, 22:306–308.
43.
OieS., SawaA., KamiyaA., and MizunoH.. 1999. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J. Antimicrob. Chemother., 44:689–691.
44.
Clinical and Laboratory Standards Institute. 2012. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically—Approved Standard. 9th ed. CLSI document M07-A9. Wayne, PA.
45.
Clinical and Laboratory Standards Institute. 2014. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. CLSI document M100-S24. Wayne, PA.
46.
BarryA.L., MillerG.H., HareR.S., JonesR.N., and ThornsberryC.. 1984. Modification of interpretive breakpoints for netilmicin disk susceptibility tests with Pseudomonas aeruginosa. J. Clin. Microbiol., 19:311–314.
47.
BarryA.L., ThornsberryC., JonesR.N., and GerlachE.H.. 1981. Gentamicin, tobramycin, and sisomicin disc susceptibility tests. Revised zone standards for interpretation. Am. J. Clin. Pathol., 75:524–531.
48.
AlmaghrabiR., ClancyC.J., DoiY., HaoB., ChenL., ShieldsR.K., PressE.G., IovineN.M., TownsendB.M., WagenerM.M., KreiswirthB., and NguyenM.H.. 2014. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob. Agents Chemother., 58:4443–4451.
49.
WatkinsD., KumarS., GreenK.D., AryaD.P., and Garneau-TsodikovaS.. 2015. Influence of linker length and composition on enzymatic activity and ribosomal binding of neomycin dimers. Antimicrob. Agents Chemother., 59:3899–3905.
50.
MeletiadisJ., MoutonJ.W., MeisJ.F., and VerweijP.E.. 2003. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother., 47:106–117.
51.
HawkeyP.M., and JonesA.M.. 2009. The changing epidemiology of resistance. J. Antimicrob. Chemother., 64Suppl 1:i3-i10.
52.
GrallN., LazarevicV., GaiaN., CouffignalC., LaouenanC., Ilic-HabensusE., WiederI., PlesiatP., AngebaultC., BougnouxM.E., Armand-LefevreL., AndremontA., DuvalX., and SchrenzelJ.. 2017. Unexpected persistence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the faecal microbiota of hospitalised patients treated with imipenem. Int. J. Antimicrob. Agents., 50:81–87.
53.
HansenK.C.M., SchwensenS. A. F., HenriksenD.P., JustesenU.S., and SydenhamT.V.. 2017. Antimicrobial resistance in the Bacteroides fragilis group in faecal samples from patients receiving broad-spectrum antibiotics. Anaerobe, 47:79–85.
54.
ChuanchuenR., BeinlichK., HoangT.T., BecherA., Karkhoff-SchweizerR.R., and SchweizerH.P.. 2001. Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob. Agents Chemother., 45:428–432.
55.
YadavR., LandersdorferC.B., NationR.L., BoyceJ.D., and BulittaJ.B.. 2015. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother., 59:2286–2298.
56.
ClockS.A., TabibiS., AlbaL., KubinC.J., WhittierS., and SaimanL.. 2013. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis., 76:343–346.
57.
PrincipeL., CaponeA., MazzarelliA., D'ArezzoS., BordiE., Di CaroA., and PetrosilloN.. 2013. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Microb. Drug Resist., 19:407–414.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
